It has been a long wait, but we are defiantly in the right direction now. If we get the predicted patient results in regard to the Phase 2A trial things are looking good for MOST IMPORTANTLY patients followed by a substantial return for SHAREHOLDERS.
- Forums
- ASX - By Stock
- PTX
- General information
PTX
prescient therapeutics limited
Add to My Watchlist
3.92%
!
4.9¢

General information, page-42
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
4.9¢ |
Change
-0.002(3.92%) |
Mkt cap ! $39.46M |
Open | High | Low | Value | Volume |
5.2¢ | 5.2¢ | 4.9¢ | $33.68K | 683.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 416902 | 4.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
5.0¢ | 700804 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 416902 | 0.048 |
1 | 10659 | 0.047 |
5 | 472791 | 0.046 |
5 | 194333 | 0.045 |
2 | 29727 | 0.044 |
Price($) | Vol. | No. |
---|---|---|
0.050 | 700804 | 2 |
0.051 | 35121 | 2 |
0.053 | 50000 | 1 |
0.055 | 300000 | 2 |
0.056 | 57000 | 2 |
Last trade - 11.28am 18/06/2025 (20 minute delay) ? |
Featured News
PTX (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online